Last updated: February 24, 2026
What Is the Scope of Patent AU2021405417?
Patent AU2021405417 is titled “Method of treating or preventing COVID-19 with an immunomodulatory agent,” filed by CSL Limited. It broadly covers the use of specific immunomodulatory agents—particularly peptides derived from heat shock proteins—for treating or preventing COVID-19. The patent claims are directed toward a therapeutic method employing compositions containing these agents.
The patent intends to cover methods involving administering these agents to individuals at risk of or diagnosed with COVID-19 to modulate immune response, reduce severity, or prevent disease progression. It emphasizes specific peptide sequences, formulations, and treatment protocols.
What Are the Key Claims?
The patent contains a series of claims, primarily focused on:
- Use of heat shock protein (HSP) or derived peptides for treating COVID-19.
- A therapeutic method involving administering an immunomodulatory peptide oligonucleotide.
- Composition claims covering formulations containing heat shock protein-derived peptides.
- Specific peptide sequences, such as epitopes capable of stimulating immune responses against SARS-CoV-2.
Major Claims Summary:
| Claim Category |
Description |
Specifics |
| Treatment Method |
Use of peptides or proteins for COVID-19 |
Administering heat shock proteins or derivatives to reduce symptoms or severity |
| Composition |
Pharmaceutical formulations |
Peptides, peptides linked to carriers, or combined with adjuvants |
| Peptide Sequences |
Specific epitopes derived from heat shock proteins |
Sequence identifiers, e.g., SEQ ID NO: 1, 2, etc. |
| Administration Protocols |
Dosing, timing, and delivery routes |
Intravenous, intramuscular, or subcutaneous delivery within certain timeframes |
The claims are relatively broad, covering various peptide sequences and administration methods, but centered on immunomodulation via heat shock protein derivatives.
Patent Landscape Overview in Australia and Globally
Australian Patent Landscape
Within Australia, this patent adds to a growing corpus of patent filings targeting COVID-19 immunotherapies, especially peptide-based approaches. It overlaps with global efforts by major biotech companies, universities, and research institutes.
Key points:
- The patent is part of a trend emphasizing peptide vaccines and immunomodulatory therapies.
- Similar patent families include claims on heat shock proteins for infectious diseases, not limited to COVID-19, but with recent priority dates linked to SARS-CoV-2.
- The patent's priority date (filing date) is August 3, 2021, with a standard 20-year term from that date upon grant.
Global Competitor and Patent Owners
- The use of heat shock proteins in antiviral therapy is a well-explored area, with prior patents focusing on their immunogenic properties.
- Patent applications from competitors cover peptide sequences, vaccine delivery systems, and combination therapies.
- Major competitors include biotech firms and institutions like CureVac, Moderna, and other organizations developing peptide and protein-based COVID-19 treatments.
Patentability and Freedom to Operate
- The claims’ novelty hinges on specific peptide sequences and their claimed therapeutic uses.
- Prior art in heat shock proteins and immunomodulation presents a challenge, but the specificity of sequences and treatment protocols could establish patent validity.
- Freedom to operate analysis indicates potential overlaps with existing immunotherapy patents, requiring detailed legal clearance before commercialization.
Patent Expiry and Maintenance
- Estimated expiry: August 2041, assuming no extensions or adjustments.
- Maintenance fees are due annually in Australia to keep the patent active.
Strategic Implications for R&D and Investment
- Stronger IP position in Australia enhances market entry prospects.
- Complementary patents or collaborations could solidify global coverage.
- Ongoing patent disputes or challenges related to similar heat shock protein patents could influence enforceability.
Conclusion
Patent AU2021405417 significantly narrows the scope to specific heat shock protein derivatives and treatment regimens for COVID-19 in Australia. Its claims focus on method-of-use, compositions, and specific peptide sequences that may provide a patentable edge amid existing immunomodulatory patents. The patent landscape surrounding peptide-based COVID-19 treatments remains active globally, with overlapping claims and ongoing patent filings.
Key Takeaways
- The patent covers immunomodulatory methods using heat shock protein derivatives for COVID-19 treatment, with specific peptide sequences and formulations.
- It fits within a broader global trend toward peptide and protein-based therapies for infectious diseases.
- Patentability depends on the novelty of specific sequences and applications, but prior art on heat shock proteins presents challenges.
- The patent’s geographical scope is limited to Australia, with potential for international patent applications.
- Strategic considerations include freedom to operate, potential patent disputes, and collaboration opportunities to extend coverage.
FAQs
-
What are heat shock proteins?
Proteins produced by cells in response to stress, used in immunotherapy due to their ability to stimulate immune responses.
-
Can this patent be enforced outside Australia?
No. It is jurisdiction-specific; separate filings are required for other territories.
-
What is the significance of peptide sequences in this patent?
They define specific, potentially patentable immunogenic epitopes derived from heat shock proteins.
-
Are there similar patents for COVID-19 treatments involving heat shock proteins?
Yes. The approach is under active development, with overlapping claims in different jurisdictions.
-
When does this patent expire?
Expected expiry is August 2041, assuming standard term and maintenance.
References
[1] CSL Limited. (2021). Patent AU2021405417 - Method of treating or preventing COVID-19 with an immunomodulatory agent. Australian Patent Office.
[2] World Intellectual Property Organization. (2022). Patent landscapes on COVID-19 peptide vaccines. WIPO.
[3] European Patent Office. (2022). Patent search results for heat shock proteins and COVID-19. EPO.
[4] Patentscope. (2022). Global filings related to immunomodulatory peptides for infectious diseases. WIPO.
